IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?

Giovanni Triolo, Giuliana Guggino, Francesco Ciccia, Vasiliki Liakouli, Francesco Carubbi, Paola Di Benedetto, Saverio Alvaro, Piero Ruscitti, Onorina Berardicurti, Roberto Giacomelli, Paola Cipriani

Risultato della ricerca: Article

35 Citazioni (Scopus)

Abstract

Although in the past the prevention of joint destruction in rheumatoid arthritis (RA) was strongly emphasized, now a great interest is focused on associated comorbidities in these patients. Multiple data suggest that a large percentage of RA patients are affected by Type 2 Diabetes (T2D), whose incidence has reached epidemic levels in recent years, thus increasing the health care costs. A better knowledge about the pathogenesis of these diseases as well as the mechanisms of action of drugs may allow both policy designers and physicians to choose the most effective treatments, thus lowering the costs. This review will focus on the role of Interleukin (IL)-1β in the pathogenesis of both the diseases, the efficacy of IL-1 blocking molecules in controlling these diseases, and will provide information suggesting that targeting IL-1β, in patients affected by both RA and T2D, may be a promising therapeutic choice.
Lingua originaleEnglish
pagine (da-a)849-855
Numero di pagine7
RivistaExpert Review of Clinical Immunology
Volume12
Stato di pubblicazionePublished - 2016

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Fingerprint Entra nei temi di ricerca di 'IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?'. Insieme formano una fingerprint unica.

  • Cita questo

    Triolo, G., Guggino, G., Ciccia, F., Liakouli, V., Carubbi, F., Di Benedetto, P., Alvaro, S., Ruscitti, P., Berardicurti, O., Giacomelli, R., & Cipriani, P. (2016). IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? Expert Review of Clinical Immunology, 12, 849-855.